This commentary examines the progressive decline in biologic efficacy in inflammatory bowel disease, highlighting pharmacologic, immunologic, and cellular mechanisms of resistance. It advocates for early, biomarker-guided, and mechanistically informed sequencing to preserve long-term therapeutic response and overcome the emerging "therapeutic ceiling."
The Importance of Treatment Timing and Positioning in IBD
Fantini M. C.Secondo
Writing – Original Draft Preparation
;Favale A.Penultimo
Writing – Review & Editing
;
2026-01-01
Abstract
This commentary examines the progressive decline in biologic efficacy in inflammatory bowel disease, highlighting pharmacologic, immunologic, and cellular mechanisms of resistance. It advocates for early, biomarker-guided, and mechanistically informed sequencing to preserve long-term therapeutic response and overcome the emerging "therapeutic ceiling."
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
izaf282.pdf
Solo gestori archivio
Tipologia:
versione editoriale (VoR)
Dimensione
268.55 kB
Formato
Adobe PDF
|
268.55 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
Valdiserra G, et al. - AAM - coverpage-iris-unica.pdf
embargo fino al 13/11/2026
Tipologia:
versione post-print (AAM)
Dimensione
939.3 kB
Formato
Adobe PDF
|
939.3 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
